AntaresRX develops precision medicines by integrating predictive sciences and advanced medicinal chemistry to address previously undruggable targets. The company focuses on creating first-in-class allosteric inhibitors for validated targets, accelerating the discovery of novel small molecule therapeutics for serious diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many critical disease targets, particularly transcription factors, have historically been considered undruggable due to limitations in conventional small molecule discovery approaches. This lack of effective therapeutic intervention for such targets hinders the development of novel treatments for serious diseases.
Solution
AntaresRX develops precision medicines by integrating predictive sciences, advanced medicinal chemistry, and target biology to address previously undruggable targets. The company focuses on creating first-in-class or best-through-first allosteric inhibitors for validated targets, aiming to deliver transformational therapies. By leveraging proprietary compound libraries, next-generation mass spectrometry, and innovative pocket-finding methodologies, AntaresRX accelerates the discovery and development of novel small molecule therapeutics. Their approach utilizes human genetics, experimental models, and functional genomics to identify disease vulnerabilities and validate high-value targets.
Target Audience
AntaresRX targets patients with serious diseases, particularly those with cancer, by developing novel precision medicines. Their approach is also relevant to biopharmaceutical companies seeking to advance drug candidates through strategic partnerships.
Features
- Integration of predictive sciences, including physics-based modeling, advanced machine learning, and molecular dynamics, with proprietary algorithms for drug discovery.
- Application of proprietary compound libraries and a next-generation mass spectrometry platform for experimental and computational analysis.
- Utilization of innovative pocket-finding approaches to identify novel chemical pockets for therapeutic intervention.
- Focus on first-in-class targets or "best-through-first" allosteric approaches to clinically validated targets, emphasizing improvements in selectivity and tolerability.
- Employment of human genetics, experimental model systems, and functional genomics to discover disease vulnerabilities and validate targets.
- Development of brain-penetrant, selective inhibitors, such as PARP1 inhibitors, for therapeutic applications.
- Collaboration with biopharmaceutical partners to advance a pipeline of small molecule assets.